Abbott to collaborate with Astellas in CMV vaccine trial Abbott announced that it has signed an agreement to collaborate with Astellas Pharma Global Development in a Phase 3 clinical trial for ASP0113, an investigational vaccine licensed from Vical Incorporated for preventing cytomegalovirus reactivation in transplant patients. Under the agreement, Abbott's RealTime CMV assay, which is performed on the Abbott m2000 System and intended for investigational use only, will be used to monitor patients for CMV viral load in order to assess the vaccine's efficacy.
News For ABT From The Last 14 Days
Check below for free stories on ABT the last two weeks.
Subscribe for More Information